FT selects Alzheimer’s Research UK as 2017/18 Seasonal Appeal partner

TBH LP - Image 4

By Philip Tubby | Wednesday 12 July 2017

The Financial Times has chosen Alzheimer’s Research UK as its 2017/2018 charity seasonal appeal partner.

Alzheimer’s Research UK is the largest charity funder of dementia research in Europe, conducting pioneering research to find better diagnosis, preventions and treatments for dementia.

The FT seasonal appeal raises money and increases awareness of a chosen charity through dedicated editorial coverage of its work. Charity partners are selected by FT employees, and readers and corporate partners are encouraged to donate. FT appeals have raised more than £17 million for charities over the last decade.

Dementia currently affects nearly 47 million people worldwide and will soon be the biggest cause of death in the UK. Alzheimer’s Research UK is leading the global fightback against the condition. Its scientists have made some of the most significant discoveries in understanding the diseases leading to dementia over the last 20 years. Through pioneering initiatives such as its Drug Discovery Alliance – which the FT seasonal appeal will support – the charity is translating these breakthroughs into the first life-changing treatment for people with dementia. Alzheimer’s Research UK campaigns to put dementia on the political agenda as well as continually working to improve understanding of a condition that is beset by misconceptions and stigma.

FT deputy editor and head of the seasonal appeal committee Roula Khalaf said:

“The Financial Times is delighted to work with Alzheimer’s Research UK for this year’s seasonal appeal. With an increasingly ageing population in most countries around the world, the global challenge dementia poses cannot be overlooked. FT journalists will highlight the charity’s groundbreaking research and give a voice to the people affected by the condition.”

Ian Wilson, Executive Director of Alzheimer’s Research UK, said:

“Dementia is now our greatest medical challenge. The global cost of the condition is expected to reach $1 trillion next year, and behind this stark figure are countless individuals, lives that have been ripped apart by diseases that rob people of their ability to think, reason and remember. With no treatments to stop or slow these diseases, there are no dementia survivors – but research has the power to change this. We are thrilled to be working with the Financial Times for this partnership. Their backing will offer a vital boost to the search for new treatments and help bring much-needed awareness and public understanding to this issue.”

See coverage from last year’s seasonal appeal on FT.com, and for more information on Alzheimer’s Research UK, visit alzheimersresearchuk.org. Charities interested in applying for the 2018-2019 seasonal appeal can find further information here.


By submitting a comment you agree to our comments policy.
Please do not post any personal information about yourself or anyone else, especially any health data or other sensitive data. If you do submit sensitive data, you consent to us handling it in line with our comments policy.

Leave a Comment

About the author

Philip Tubby